A Phase 3 interventional study of CAM2029 and Octreotide LAR in Gastro-enteropancreatic Neuroendocrine Tumor, sponsored by Camurus AB. Active, not recruiting at 86 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Camurus AB · Phase 3, Interventional, and Treatment
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.
72 studies on the registry are indexed under Gastro-enteropancreatic neuroendocrine tumor; 24 are open to participants now.
This study's enrollment of 332 is above the median of 53 across 48 interventional studies indexed under Gastro-enteropancreatic neuroendocrine tumor.
Browse Gastro-enteropancreatic neuroendocrine tumor studies →Camurus AB is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CAM2029
Drug: Octreotide LAR · Drug: Lanreotide ATG
Drug pages: Octreotide hydrochloride · Octreotide Depot Formulation CAM2029
CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection
Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection
Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection
Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)
PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first)
Time frame: From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months
Overall survival
The time from the date of randomization to the date of death due to any cause
Time frame: Up to 2 years following the primary efficacy analysis
PFS as assessed by local Investigators
PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first)
Time frame: From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months
Overall response rate
The proportion of patients with best overall response of complete response (CR) or partial response (PR), as per BIRC according to RECIST 1.1
Time frame: From date of randomization until disease progression, assessed up to 48 months
Disease control rate
The proportion of patients with a best overall response of CR, PR or stable disease (SD), as per BIRC according to RECIST 1.1
Time frame: From date of randomization until disease progression, assessed up to 48 months
Time to tumor response
The time from the date of randomization to the first documented response of CR or PR, as per BIRC according to RECIST 1.1
Time frame: From date of randomization until disease progression, assessed up to 48 months
Duration of response
The time from the date of the first documented response of CR or PR to the date of the first documented progression or death due to underlying cancer, as per BIRC according to RECIST 1.1
Time frame: From date of randomization until disease progression or death due to underlying cancer, whichever comes first, assessed up to 48 months
Incidence of treatment-emergent adverse events
Time frame: From screening to the safety follow-up, assessed up to 6 years
Plan to share: No
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Octreotide hydrochloride · Octreotide Depot Formulation CAM2029
Gastro-enteropancreatic neuroendocrine tumor →
Camurus AB